Spots Global Cancer Trial Database for relugolix
Every month we try and update this database with for relugolix cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases | NCT04523207 | Prostatic Neopl... | Apalutamide ADT Relugolix | 18 Years - | Janssen Research & Development, LLC | |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score | NCT05050084 | Prostate Adenoc... | Bicalutamide Buserelin Darolutamide Degarelix Flutamide Goserelin Histrelin Leuprolide Radiation Thera... Relugolix Triptorelin | 18 Years - | NRG Oncology | |
| Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer | NCT06129851 | Stage IIC Prost... Stage III Prost... Stage IV Prosta... | Biospecimen Col... Bone Scan Brachytherapy Computed Tomogr... Dual X-ray Abso... External Beam R... Magnetic Resona... PSMA PET Scan Questionnaire A... Relugolix | 18 Years - | University of Kansas Medical Center | |
| RElugolix VErsus LeUprolide Cardiac Trial | NCT05320406 | Biochemically R... Localized Prost... Stage I Prostat... Stage II Prosta... Stage IIA Prost... Stage IIB Prost... Stage IIC Prost... Stage III Prost... Stage IIIA Pros... Stage IIIB Pros... Stage IIIC Pros... | Radiation thera... Leuprolide Relugolix | 18 Years - | Emory University | |
| Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy | NCT04756037 | Contraception | Relugolix Combi... | 18 Years - 50 Years | Sumitomo Pharma Switzerland GmbH | |
| Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer | NCT04666129 | Metastatic Cast... Metastatic Cast... Non-Metastatic ... | Relugolix Abiraterone Prednisone Methylprednisol... Apalutamide Docetaxel | 18 Years - | Sumitomo Pharma Switzerland GmbH | |
| A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer | NCT03085095 | Prostate Cancer | Relugolix Leuprolide Acet... | 18 Years - | Myovant Sciences GmbH | |
| A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer | NCT03085095 | Prostate Cancer | Relugolix Leuprolide Acet... | 18 Years - | Myovant Sciences GmbH | |
| Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer | NCT06330805 | Prostate Adenoc... Stage IIB Prost... Stage IIC Prost... | Biospecimen Col... Contrast Agent Leuprolide Magnetic Resona... Physical Perfor... Relugolix | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate | NCT05605964 | Prostate Cancer | Relugolix Leuprolide Acet... | 18 Years - | Sumitomo Pharma Switzerland GmbH | |
| A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer | NCT02083185 | Prostate Cancer | Relugolix Leuprorelin | 18 Years - | Takeda | |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids | NCT02655237 | Uterine Fibroid... | Relugolix Relugolix Place... Leuprorelin Leuprorelin Pla... | 20 Years - | Takeda | |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids | NCT02655237 | Uterine Fibroid... | Relugolix Relugolix Place... Leuprorelin Leuprorelin Pla... | 20 Years - | Takeda | |
| Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer | NCT04666129 | Metastatic Cast... Metastatic Cast... Non-Metastatic ... | Relugolix Abiraterone Prednisone Methylprednisol... Apalutamide Docetaxel | 18 Years - | Sumitomo Pharma Switzerland GmbH | |
| A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX | NCT05467176 | Prostate Cancer | Relugolix | 18 Years - | Sumitomo Pharma Switzerland GmbH | |
| A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | NCT05862272 | Uterine Fibroid... Endometriosis | Relugolix Combi... | 18 Years - 50 Years | Sumitomo Pharma Switzerland GmbH | |
| RecoverPC: Relugolix vs GnRH Agonist in Quality of Life | NCT05765500 | Prostate Cancer Prostatic Neopl... | Relugolix Leuprolide | 18 Years - | Dana-Farber Cancer Institute | |
| Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial | NCT06378866 | Recurrent Castr... Stage IVB Prost... Recurrent Prost... Castration-resi... | Abiraterone Apalutamide Biospecimen Col... Bone Scan Computed Tomogr... Darolutamide Degarelix Enzalutamide Goserelin Histrelin Leuprolide Magnetic Resona... Patient Observa... Positron Emissi... Prednisone Questionnaire A... Relugolix Stereotactic Bo... Triptorelin | 18 Years - | Mayo Clinic | |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | NCT04423211 | Biochemically R... Metastatic Pros... Prostate Adenoc... Stage IVB Prost... | 3-Dimensional C... Apalutamide Computed Tomogr... Degarelix External Beam R... Fluciclovine F1... Goserelin Aceta... Intensity-Modul... Intensity-Modul... Leuprolide Acet... Magnetic Resona... Positron Emissi... Quality-of-Life... Questionnaire A... Relugolix Stereotactic Bo... Triptorelin Volume Modulate... | 18 Years - | Eastern Cooperative Oncology Group | |
| A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer | NCT02083185 | Prostate Cancer | Relugolix Leuprorelin | 18 Years - | Takeda | |
| RElugolix VErsus LeUprolide Cardiac Trial | NCT05320406 | Biochemically R... Localized Prost... Stage I Prostat... Stage II Prosta... Stage IIA Prost... Stage IIB Prost... Stage IIC Prost... Stage III Prost... Stage IIIA Pros... Stage IIIB Pros... Stage IIIC Pros... | Radiation thera... Leuprolide Relugolix | 18 Years - | Emory University | |
| A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids | NCT02655224 | Uterine Fibroid... | Relugolix Relugolix place... | 20 Years - | Takeda | |
| Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer | NCT06330805 | Prostate Adenoc... Stage IIB Prost... Stage IIC Prost... | Biospecimen Col... Contrast Agent Leuprolide Magnetic Resona... Physical Perfor... Relugolix | 18 Years - | Ohio State University Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
